TABLE 2

Body weight, waist circumference, and FPG and 2-h postload plasma glucose concentrations

VariableTime (years)Placebo
Metformin
Troglitazone
ILS
nMeannMeannMeannMean
Body weight (kg)0.058294.658794.558593.358995.5
0.538494.538992.837895.238688.1
1.018295.317293.319697.019189.7
1.55897.65994.37298.05391.1
Waist circumference (cm)0.0582105.6586105.0585104.3588106.1
1.0180105.1172104.4197105.7191100.4
FPG (mmol/l)0.05825.965875.965855.965895.98
0.53885.973945.723835.633885.71
1.01826.001725.801975.661905.75
1.5586.27615.88725.74546.00
2-h plasma glucose (mmol/l)0.05829.225879.195859.185899.19
1.01748.791728.811968.031887.86
  • None of the variables differed significantly between treatment groups at baseline (time = 0). By repeated-measures ANOVA, the troglitazone group differed significantly from each of the others (P < 0.05 adjusted for three comparisons) for body weight and FPG. It differed significantly from the ILS group for waist circumference and from the placebo and metformin groups in 2-h plasma glucose. n, number of participants with the measurement at each time point. Conversion of units for glucose: 1 mg/dl = 0.05551 mmol/l.